Investigational Drug Information for Cediranib
✉ Email this page to a colleague
What is the development status for investigational drug Cediranib?
Cediranib is an investigational drug.
There have been 102 clinical trials for Cediranib.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 6th 2008.
The most common disease conditions in clinical trials are Carcinoma, Ovarian Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), AstraZeneca, and NRG Oncology.
Summary for Cediranib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,277 |
| WIPO Patent Applications | 639 |
| Japanese Patent Applications | 181 |
| Clinical Trial Progress | Phase 3 (2008-11-06) |
| Vendors | 63 |
Recent Clinical Trials for Cediranib
| Title | Sponsor | Phase |
|---|---|---|
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents | NRG Oncology | Phase 2 |
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents | National Cancer Institute (NCI) | Phase 2 |
| Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer | National Cancer Institute (NCI) | Phase 2 |
Clinical Trial Summary for Cediranib
Top disease conditions for Cediranib
Top clinical trial sponsors for Cediranib
US Patents for Cediranib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
